AgomAb Therapeutics N.V. American Depositary Shares
AGMBAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 22, 2026 | H.C. Wainwright | Patrick Trucchio | $35.00(+219%) | $10.98 | TheFly |
Earnings History
Next report: Mar 3, 2027 · EPS est. $-0.95| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.89 | $1.18 | — | — |
| Apr 23, 2026 | $-45.69 | $-0.52 | — | — |
| Feb 25, 2026 | $-0.36 | $-0.52 | — | — |
News
Antwerp, Belgium, November 4, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Conference. Fireside chat on Tuesday, November 10, 2026 at 3:30 PM ET in Boston, MA.
Agomab announced that the first patient has been dosed in NOV-ERA, the Company's Phase 2b study evaluating ontunisertib in patients with symptomatic FSCD.
AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript
Agomab Therapeutics NV (NASDAQ:AGMB) reported results from the 48-week open-label extension portion of its Phase 2a STENOVA trial of ontunisertib for fibrostenotic Crohn's disease.
-- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn's disease (FSCD) patients -- -- Low annualized FSCD-related event rate of 3%, with one endoscopic balloon dilation (EBD) and no surgeries reported over the full treatment period -- -- Radiological assessment shows trend for fibrotic stricture stabilization over treatment course -- -- Sustained disease control observed across symptoms and disease activity scores in…
AgomAb Therapeutics NV (NASDAQ: AGMB - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among analysts
Agomab Therapeutics targets fibrotic strictures in Crohn's disease, aiming to create a new treatment category rather than compete with existing therapies. AGMB's ontunisertib showed promising endoscopic results and safety in Phase 2a, with further validation needed in larger, controlled trials. Strong funding runway through 2029 and disciplined R&D execution support AGMB's ability to advance clinical programs without immediate dilution risk.
-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in the lung, in line with prior results observed in healthy participants -- -- Robust target engagement of ALK5 observed with AGMB-447 in IPF patients -- -- Clinical Trial Application (CTA) for INSPIRIA Phase 2 study in IPF patients submitted; Company intends to initiate study befor…
Agomab announced shareholders approved all resolutions submitted for consideration at the Company's Special and Extraordinary General Shareholders' Meeting
Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference. Thursday, September 10, 2026 in New York, NY.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.